Genexine

Genexine is a clinical-stage biotechnology company focused on the development of innovative immunotherapies and the commercialization of next-generation novel long-acting biologics. Genexine began clinical trials with its proprietary biologics in 2013 and has continued to advance its pipeline through clinical trials and deals in Europe and Asia, achieving considerable success. GX-H9, a long-acting human growth hormone for growth hormone deficiency in children and adults, is currently undergoing Phase II clinical trials in the EU and South Korea. GX-E2 (a long-acting treatment for anemia), GX-G3 (for neutropenia), and GX-188E (a therapeutic vaccine for HPV-induced cervical intraepithelial neoplasia) are also currently in Phase II clinical trials in South Korea and overseas.